China Colorectal Cancer Screening Trial 2 (C-Cost2)

Официальное название

China Colorectal Cancer Screening Trial 2 (C-Cost2): FIT Versus FIT-sDNA in the Average Risk Population

Обзор

Colorectal cancer (CRC) is one of the most common malignancies in China. Currently, its incidence rate is increasing at a rate of 4% per year, exceeding the global annual average growth rate. Screening and early diagnosis of colorectal cancer and precancerous lesions are key measures to reduce the disease burden of colorectal cancer in China. In previous clinical studies, colorectal cancer screening in high risk population received extensive attention. However, it cannot be ignored that the majority of sporadic colorectal cancers occur in the average risk population. Therefore, there is an urgent need to develop new approach for colorectal cancer screening in the average risk population in China. Fecal Immunochemical Testing (FIT) initial screening followed by diagnostic colonoscopy is widely recommended by colorectal cancer screening guidelines worldwide. The current colorectal cancer screening approach faces challenges including limited sensitivity of initial screening technologies and insufficient population coverage in organized screening programs in China. Stool DNA tests detect DNA biomarkers of tumor cells in the stool and have higher sensitivity in detecting advanced colorectal neoplasms. USPSTF has recommended FIT-sDNA as initial screening tests in the average risk population. Colorectal Cancer Early Screening in China (Clear-C) trial has reported FIT-sDNA had higher sensitivity than FIT in detecting advanced colorectal neoplasms among high risk population, yet there is a lack of randomized controlled trials (RCTs) directly comparing the effectiveness of FIT and FIT-sDNA for colorectal cancer screening in the average risk population in China. In China Colorectal Cancer Screening Trial 2 (C-Cost2), we propose to perform a multicenter, individual-level randomized, parallel group trial directly comparing FIT and FIT-sDNA in the average risk population in China. The main research hypothesis is that the screening protocol of FIT-sDNA group (Group B) has a superior detection rate of advanced colorectal neoplasms compared to the FIT group (Group A).

Подробное описание

This study intends to recruit participants who meet the above inclusion and exclusion criteria in China, with the goal of recruiting at least 7504 eligible participants at baseline. The study adopts an individual-level randomized design. After signing the informed consent form, eligible participants will be randomly assigned to 2 colorectal cancer screening groups. All participants will undergo a 4-year screening phase, and then all participants will be followed up for a long term. Fecal, blood, and tissue samples will be collected from the participants during the study. The grouping and specific intervention measures are as follows:

1. FIT group (n = 3752): The internationally recommended screening protocol is adopted. In the first 4 years of the screening phase, all participants will receive annual FIT tests. Participants with positive FIT results are recommended to undergo diagnostic colonoscopy. Suspicious lesions detected during the colonoscopy will be resected and further sent for pathological examination. Participants who refuse FIT tests, have negative FIT tests, have positive FIT tests but do not receive diagnostic colonoscopy will be screened again in the first 4 years. All the participants will be followed by long-term follow-ups. 2. FIT-sDNA group (n = 3752): A new screening protocol is adopted. In the first 4 years of the screening phase, all participants will receive annual FIT-sDNA tests. Participants with positive FIT-sDNA results are recommended to undergo diagnostic colonoscopy. Suspicious lesions detected during the colonoscopy will be resected and further sent for pathological examination. Participants who refuse FIT-sDNA tests, have negative FIT-sDNA tests, have positive FIT-sDNA tests but do not receive diagnostic colonoscopy will be screened again in the first 4 years. All the participants will be followed by long-term follow-ups.

Вмешательства

• Диагностический тест FIT
  FIT stands for Fecal Immunochemical Test, a non-invasive screening tool used primarily to detect hidden blood in the stool, which may indicate colorectal cancer or precancerous polyps. Positive cut-off level: 100 ng/mL.
• Диагностический тест FIT-sDNA
  FIT-sDNA test combines Fecal Immunochemical Test (FIT) and stool DNA (sDNA) analysis. It detects hemoglobin in stool through FIT to identify occult blood in the gastrointestinal tract and simultaneously analyzes specific DNA mutations or epigenetic alterations (such as methylation changes) in stool DNA to assess the risk of colorectal neoplasms.

Первичные конечные точки

• Detection rate of advanced colorectal neoplasms [Срок оценки: 4 years]

Вторичные конечные точки (7)

• Population compliance rate [Срок оценки: 4 years]
• Proportion of colorectal cancer at different stages [Срок оценки: 4 years]
• Incidence rate of colorectal cancer [Срок оценки: 10 years]
• Mortality rate of colorectal cancer [Срок оценки: 10 years]
• Quality of life (QOL) [Срок оценки: 4 years]
• Total cost and cost per detected lesion [Срок оценки: 4 years]
• Incremental cost-effectiveness ratio [Срок оценки: 4 years]

Критерии участия

Критерии включения

• Age: 45-74 years old;
• In good general condition, with normal mental state and voluntarily signing the informed consent form;

Критерии исключения

• Personal history of colorectal cancer or precancerous lesions;
• History of previous colonrectal resection surgery;
• Diagnosed with cancer before enrollment or currently receiving any cancer-related treatment;
• Having received colonoscopy, flexible sigmoidoscopy, CT colonography and other examinations within the past 5 years;
• Having received FIT or FIT-sDNA or cfDNA test within the past 1 year;
• Symptomatic lower gastrointestinal diseases or symptoms suggesting the need for diagnostic colonoscopy for confirmation;
• Accompanied by severe diseases that are not suitable for colorectal cancer screening;

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Скрининг

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07090304 · C-Cost2

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗